Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week's Bonus Article
Intuitive Surgical's Selloff Sets Up a 30% Rebound OpportunityWritten by Thomas Hughes. First Published: 4/23/2026. 
Key Points
- Instuitive Surgical hit bottom in early 2026 and is set up to rebound robustly.
- Accelerting device placement, procedure volume, and consumable supplies underpin the growth outlook.
- Competition exists but trails significantly, leaving this company with a wide moat.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Intuitive Surgical’s (NASDAQ: ISRG) primary headwinds are its high valuation and slowing growth. Those factors have weighed on the stock since early 2025, but the current valuation already embeds a strong growth outlook and may still understate the company’s longer-term potential. Intuitive Surgical’s promise is its dominance in robotic surgical procedures. The company has a first-mover advantage with an installed base of more than 12,000 systems and counting. In that context, a roughly 45X multiple on current-year earnings is a manageable hurdle, given the potential for a 50% (or greater) increase in the stock price over the next few years.
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
That assumes the long-term forecasts are accurate. To date, Intuitive Surgical routinely beats expectations, and device deployments and procedure volumes continue to expand. The more likely outcome is that ISRG continues to outperform and sparks a bullish revision cycle over time. Market Overreaction Sets Up ISRG OpportunityAnalysts played a role in ISRG’s stock decline in 2026. Price-target cuts were the trend ahead of the fiscal Q1 2026 release, but the market overreacted, creating a deep-value opportunity. The revision trend reinforces the consensus target, which implies more than 30% upside from important support levels, and there is high conviction in that outlook. MarketBeat tracks 25 analysts who rate the stock a consensus Moderate Buy, with a 68% buy-side bias that is mirrored in institutional activity. The institutional ownership is instructive. Institutions own more than 80% of the stock and have been accumulating through the corrective period. Buying ramped into Q1 2026 and remained strong in early Q2. The trailing 12-month balance is nearly 2-to-1 in favor of buyers, with Q1 and Q2 activity reflecting accelerating demand. The takeaway: ISRG appears to have a solid floor in the $445–$450 range and is positioned for a robust rebound in Q2 and later in 2026. Price action mirrors institutional behavior, with declines arrested near $445 and subsequent rebounds. The mid-Q2 setup points to further upside: the market is showing support at that critical level and advanced after the Q1 release. Technical indicators such as the MACD and stochastic are aligned, suggesting a trend-following move that could push the stock back toward record highs. Key technical hurdles include the long-term 150-day exponential moving average near $500 and resistance at prior peaks around $560 and $600. Buybacks Add Leverage: Underpin Stock Price OutlookShare repurchases are another reason the stock can reach new highs. In addition to operational outperformance and improving forward estimates, buybacks have increased shareholder leverage. The Q1 release showed more than $1.1 billion in repurchases, which reduced the share count roughly 0.15% sequentially and about 1.3% year over year, and management has capacity to continue buying shares at a robust pace. Buybacks and acquisitions have lowered cash balances, but strong cash flow and declining liabilities have preserved overall balance-sheet strength. Intuitive Surgical maintains a zero-debt position and remains net cash relative to total liabilities, with cash exceeding liabilities by more than 3.15x — among the strongest balance sheets on Wall Street. Intuitive Surgical’s Q1 Release Triggers Market ReboundIntuitive Surgical posted a robust Q1 that reaffirmed its growth trajectory and suggested forward estimates could be conservative. Net revenue of $2.77 billion rose 23.1% year over year, outperforming consensus by roughly 550 basis points. Growth was driven by device placements (up 17%), procedure volume (up 17%), and instrument sales (up 23%). The installed base grew 12%, supporting continued gains in coming quarters, and margins improved. Adjusted net income grew 36%, outpacing revenue growth by more than 1,300 basis points, and management expects profitability to remain strong in the quarters ahead. Guidance calls for full-year da Vinci device growth of approximately 14.5%, with procedures and instrument sales rising in line. The biggest risk beyond valuation is competition, though rivals remain well behind. The closest challenger, Medtronic’s (NYSE: MDT) Hugo platform, has seen traction overseas but is still in early rollout stages. Potential catalysts for ISRG include the initial success of da Vinci 5, AI-driven opportunities, and international expansion. Japan in particular recently approved seven new robotic procedures and is viewed as a meaningful growth market. |
Post a Comment
Post a Comment